C6Ma3
A neo-epitope fragment of the α3 chain of type VI collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of intestinal extracellular matrix remodeling and disease activity in inflammatory bowel conditions.
Key features and values
- Quantifies degradation fragments of the α3 chain of type VI collagen produced by matrix metalloproteinase activity.
- Reflects extracellular matrix remodeling associated with intestinal inflammation.
- Provides a non-invasive measure of tissue remodeling in inflammatory bowel diseases.
- Supports monitoring of disease progression and response to therapies targeting extracellular matrix remodeling.
- Applicable in research on diseases characterized by excessive extracellular matrix turnover, such as Crohn’s disease and ulcerative colitis.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The C6Ma3 biomarker assay measures specific neo-epitope fragments of the α3 chain of type VI collagen generated through matrix metalloproteinase activity, serving as an indicator of intestinal extracellular matrix remodeling. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in conditions such as Crohn’s disease and ulcerative colitis. By quantifying collagen degradation products associated with matrix metalloproteinase activity, the C6Ma3 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of extracellular matrix turnover.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
